AstraZeneca & Merck announce OlympiA phase 3 trial of Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer: Rahway, New Jersey Friday, Dec ...
The future of breast cancer screening and risk-reducing strategies is being shaped by artificial intelligence (AI), according to a recent review article.
Women with a type of low-risk cancer might not have to rush aggressive treatment, doctors say.
Tracer Biotechnologies, a next-generation diagnostics company, today announced a multi-year project with AstraZeneca (LSE/STO/Nasdaq: AZN). The agreem ...
SAN ANTONIO -- The addition of palbociclib (Ibrance) to current standard-of-care therapy following induction chemotherapy ...
More than 100 000 women older than 70 years are diagnosed with hormone receptor-positive, early-stage breast cancer each year in the USA.1 A large proportion are at low risk of disease recurrence, ...
Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.
Pfizer touts Ibrance’s status as a standard of care in HR-positive, HER2-negative metastatic breast cancer. Now the company ...
A HER2-positive status reflects breast cancer cells with extra copies of the HER2 gene, or higher expression of HER2 proteins ...
Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.
Project EVOLVE, funded by Daiichi Sankyo and AstraZeneca, to be presented at the 2024 San Antonio Breast Cancer Symposium -- NEW YORK, Dec. 12, 2024 /PRNewswire/ -- Novellia, Inc., an AI-enabled ...
The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback